TY  - JOUR
AU  - Weber, Manuel
AU  - Telli, Tugce
AU  - Kersting, David
AU  - Seifert, Robert
TI  - Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors.
JO  - Cancers
VL  - 15
IS  - 14
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2023-01547
SP  - 3581
PY  - 2023
AB  - Historically, molecular imaging of somatostatin receptor (SSTR) expression in patients with neuroendocrine tumors (NET) was performed using SSTR scintigraphy (SRS). Sustained advances in medical imaging have led to its gradual replacement with SSTR positron-emission tomography (SSTR-PET). The higher sensitivity in comparison to SRS on the one hand and conventional cross-sectional imaging, on the other hand, enables more accurate staging and allows for image quantification. In addition, in recent years, a growing body of evidence has assessed the prognostic implications of SSTR-PET-derived prognostic biomarkers for NET patients, with the aim of risk stratification, outcome prognostication, and prediction of response to peptide receptor radionuclide therapy. In this narrative review, we give an overview of studies examining the prognostic value of advanced SSTR-PET-derived (semi-)quantitative metrics like tumor volume, uptake, and composite metrics. Complementing this analysis, a discussion of the current trends, clinical implications, and future directions is provided.
KW  - NET (Other)
KW  - PET (Other)
KW  - SUV (Other)
KW  - somatostatin receptor (Other)
KW  - tumor volume (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37509242
C2  - pmc:PMC10377105
DO  - DOI:10.3390/cancers15143581
UR  - https://inrepo02.dkfz.de/record/277879
ER  -